Phoenix woman didn't let disease hold her back - Arizona Republic

Phoenix woman didn't let disease hold her back Arizona Republic When it came to dealing with the rheumatoid arthritis she battled since childhood, the Phoenix resident bent the rules. Often warned by doctors or ... and more »

Protalex, Inc. Announces Dose Escalation of First Patients in 2nd Cohort of ... - MarketWatch (press release)

Protalex, Inc. Announces Dose Escalation of First Patients in 2nd Cohort of ... MarketWatch (press release) ... of its ongoing multicenter Phase 1b clinical study of PRTX-100 in adult patients with active Rheumatoid Arthritis (RA) being conducted in South Africa. ... and more »

Incyte Achieves Million Milestone as Novel JAK1 and JAK2 Inhibitor ... - MarketWatch (press release)

Proactive Investors USA & Canada

Incyte Achieves Million Milestone as Novel JAK1 and JAK2 Inhibitor ... MarketWatch (press release) This Phase IIb clinical trial is a global, dose-ranging, study expected to involve 270 patients with active rheumatoid arthritis and is open to enrollment ... Incyte collects m from partner Eli Lilly as it begins phase IIb trial for ...Proactive Investors USA & Canada Incyte Earns M Milestone from Lilly on Start of Phase IIb Trial with RA ...Genetic Engineering News all 17 news articles »

CORRECT: NICE Not Minded To OK Merck's Simponi, Wants More Data - Wall Street Journal

CORRECT: NICE Not Minded To OK Merck's Simponi, Wants More Data Wall Street Journal Also known as golimumab, Simponi is a follow-up drug to Remicade, which treats rheumatoid arthritis and gastrointestinal conditions and which had worldwide ... NHS needs more data on rheumatoid arthritis drugWebMD.Boots.com UK NICE Appraisal Consultation on Merck & Co's Simponi for rheumatoid ...The Pharma Letter (subscription) all 8 news articles »